Hyperfine (NASDAQ:HYPR) & InMode (NASDAQ:INMD) Head-To-Head Survey

InMode (NASDAQ:INMDGet Rating) and Hyperfine (NASDAQ:HYPRGet Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Institutional & Insider Ownership

53.6% of InMode shares are owned by institutional investors. Comparatively, 22.7% of Hyperfine shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for InMode and Hyperfine, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InMode 0 0 5 0 3.00
Hyperfine 0 0 2 0 3.00

InMode presently has a consensus price target of $55.60, indicating a potential upside of 63.77%. Hyperfine has a consensus price target of $7.50, indicating a potential upside of 403.36%. Given Hyperfine’s higher probable upside, analysts plainly believe Hyperfine is more favorable than InMode.

Profitability

This table compares InMode and Hyperfine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InMode 42.66% 41.50% 35.91%
Hyperfine N/A -59.73% -26.18%

Volatility & Risk

InMode has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Valuation & Earnings

This table compares InMode and Hyperfine’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InMode $357.57 million 7.90 $164.97 million $2.01 16.89
Hyperfine $1.50 million 69.86 -$64.85 million N/A N/A

InMode has higher revenue and earnings than Hyperfine.

Summary

InMode beats Hyperfine on 8 of the 10 factors compared between the two stocks.

About InMode

(Get Rating)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

About Hyperfine

(Get Rating)

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.